UPDATE 1-Alexion gets EU approval for drug acquired in Synageva deal
September 01, 2015 at 16:03 PM EDT
NEW YORK, Sept 1 (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.